Cargando…

A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation

BACKGROUND: Olanzapine rapid-acting intramuscular (IM) injection is an atypical antipsychotic drug already used overseas and recently approved in Japan. The objective of this study was to confirm the efficacy of rapid-acting IM olanzapine 10 mg was greater than IM placebo in patients with exacerbati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katagiri, Hideaki, Fujikoshi, Shinji, Suzuki, Takuya, Fujita, Kiyoshi, Sugiyama, Naoya, Takahashi, Michihiro, Gomez, Juan-Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556331/ https://www.ncbi.nlm.nih.gov/pubmed/23311957 http://dx.doi.org/10.1186/1471-244X-13-20

Ejemplares similares

Erratum: A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation
por: Katagiri, Hideaki, et al.
Publicado: (2014)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
por: Katagiri, Hideaki, et al.
Publicado: (2018)

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study
por: Katagiri, Hideaki, et al.
Publicado: (2013)

Safety and effectiveness of rapid-acting intra-muscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
por: Katagiri, Hideaki, et al.
Publicado: (2018)

A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia
por: Suzuki, Hidenobu, et al.
Publicado: (2013)

Coadministration of intramuscular olanzapine and benzodiazepines in agitated patients with mental illness
por: Williams, Andrew M.
Publicado: (2018)

One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study
por: Ye, Wenyu, et al.
Publicado: (2012)

Remission, response, and relapse rates in patients with acute schizophrenia treated with olanzapine monotherapy or other atypical antipsychotic monotherapy: 12-month prospective observational study
por: Takahashi, Michihiro, et al.
Publicado: (2015)

Intramuscular midazolam, olanzapine, or haloperidol for the management of acute agitation: A multi-centre, double-blind, randomised clinical trial
por: Chan, Esther W., et al.
Publicado: (2021)

Evaluation of intramuscular olanzapine and ziprasidone in the medically ill
por: Patel, Seema M., et al.
Publicado: (2021)

Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia
por: Tajiri, Misuzu, et al.
Publicado: (2018)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
por: Di Lorenzo, Rosaria, et al.
Publicado: (2010)

Intramuscular Olanzapine – a UK case series of early cases
por: Bushe, Chris J, et al.
Publicado: (2007)

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
por: Citrome, Leslie
Publicado: (2009)

Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
por: Dilla, Tatiana, et al.
Publicado: (2014)

Ziprasidone, haloperidol and clonazepam intramuscular administration in the treatment of agitation symptoms in Chinese patients with schizophrenia: A network meta-analysis
por: Su, Liang, et al.
Publicado: (2018)

Intramuscular Ketamine Effect on Postnasal Surgery Agitation: A Prospective Double-Blinded Randomized Controlled Trial
por: Almajali, Husam A., et al.
Publicado: (2023)

Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
por: Ye, Wenyu, et al.
Publicado: (2011)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

A study on blood pressure changes following Olanzapine Long Acting Injection (LAI) in schizophrenia
por: Gakkhar, Shivam, et al.
Publicado: (2022)

Paroxetine combined with olanzapine in the treatment of schizophrenia
por: Wang, Ning, et al.
Publicado: (2020)

Treatment Continuation of Asenapine or Olanzapine in Japanese Schizophrenia Patients: A Propensity Score Matched Study
por: Matsuzaki, Haruna, et al.
Publicado: (2021)

Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder
por: Gao, Keming, et al.
Publicado: (2013)

Use of olanzapine to treat agitation in traumatic brain injury: study protocol for a randomised controlled trial
por: Phyland, Ruby K, et al.
Publicado: (2020)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum, Haya, et al.
Publicado: (2014)

IVIVC from Long Acting Olanzapine Microspheres
por: D'Souza, Susan, et al.
Publicado: (2014)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2011)

Early prediction of blonanserin response in Japanese patients with schizophrenia
por: Kishi, Taro, et al.
Publicado: (2014)

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
por: Ye, Wenyu, et al.
Publicado: (2012)

Conventional intramuscular sedatives versus ziprasidone for severe agitation in adolescents: case-control study
por: Jangro, William C, et al.
Publicado: (2009)

In an Emergency Setting, What Is the Best Intramuscular Pharmacological Treatment to Give to an Agitated Geriatric Patient?
por: Malone, Kevin, et al.
Publicado: (2022)

Predicting treatment outcomes of major depressive disorder by early improvement in painful physical symptoms: a pooled analysis of double-blind, placebo-controlled trials of duloxetine
por: Tokuoka, Hirofumi, et al.
Publicado: (2017)

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia
por: Lu, Mong-Liang, et al.
Publicado: (2016)

Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia
por: An, Huimei, et al.
Publicado: (2022)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: Lindenmayer, JP
Publicado: (2010)

Pharmacokinetics of olanzapine long-acting injection: the clinical perspective
por: Heres, Stephan, et al.
Publicado: (2014)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
por: Ye, Wenyu, et al.
Publicado: (2012)

Effect of Olanzapine on Clinical and Polysomnography Profiles in Patients with Schizophrenia
por: Katshu, Mohammad Zia Ul Haq, et al.
Publicado: (2018)

Phase 2 randomized placebo‐controlled study of lasmiditan for the acute treatment of migraine in Japanese patients
por: Sakai, Fumihiko, et al.
Publicado: (2021)

Characterizing the experience of agitation in patients with bipolar disorder and schizophrenia
por: Roberts, Jenna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hcr44vth09m75df8hbbj2bb9vi